COMP <GO>
DXCM vs UNH // RSI-14 & 200D SMA MOMENTUM
DexCom Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: DXCM 7
— UNH 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: UNH
LAST: $82.29 (+2.95%) • MKT CAP: $30.16B
rsi-technicals
47.8
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
rsi-technicals
56.0
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DXCM VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DXCM | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 60.10% | 88.57% | -28.47 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.60% | 11.47% | +10.13 | DXCM | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.2x | 16.4x | +8.75 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 3.57% | 6.48% | -2.91 | UNH | /fcf-yield <GO> |
| Operating Margin | 19.60% | 4.82% | +14.78 | DXCM | /operating-margins <GO> |
| Net Profit Margin | 17.90% | 3.14% | +14.76 | DXCM | /net-margins <GO> |
| Revenue Growth (YoY) | 15.60% | 6.46% | +9.14 | DXCM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.14 | 3.12 | +4.02 | DXCM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | DXCM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.74% | +0.46 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 47.8 | 56.0 | -8.30 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.33 | +0.77 | DXCM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.3x | 17.1x | +13.21 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $30.16B | $364.66B | -$334.50B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DXCM REV | UNH REV | DXCM GROSS % | UNH GROSS % | DXCM FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.66B | $447.57B | 60.1% | 88.7% | $1.08B | $16.07B |
| FY 2024 | $4.03B | $400.28B | 60.5% | 88.3% | $630.7M | $20.70B |
| FY 2023 | $3.62B | $371.62B | 44.0% | 89.6% | $585.5M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DXCM // BETA 1.10
UNH // BETA 0.33